Monumental Year Ahead For Korean Pharmas As New US Approvals Eyed
2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.
2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.